View                 Download                 XML
Authors Sheikh Abdul Khaliq,, Zahid Khan, Atiquddin Mallick, Anab Fatima
Description Retrospective study in different ethnic groups determines the burden and patterns of prostate cancer during the last eight years reported in Oncology wards of hospitals of Karachi, Pakistan. Compares the management pharmacotherapy/chemotherapy/surgery with international guidelines, develops strategies for screening and evidence based pharmacotherapy/chemotherapy/surgery of cases. Every single one male case with histologically and cytologically established prostate cancer was enrolled from January 2003 to December 2010. Data for all patients were collected retrospectively by patient’s file & charts, which represents the population of Karachi, Interior Sindh & Balochistan. 72 male patients investigated for their diagnosis of cancer type, ethnicity, age & gender. The statistical analysis was performed for mean, standard error & proportions. Screening, Pharmacotherapy/Chemotherapy/Surgery employed by the hospitals was compared with international guidelines and evidences. Proportionately major ethnic groups male diagnosed with prostate cancer in total male cases of prostate cancer was Sindhi (43%), Urdu Speaking/Immigrants (24%), Baloch (10%), Pukhtoon (8%), Punjabi (7%), Minorities & others (8%). Mean age at the time of diagnosis was 65.44±10.89 years, SE± 0.227 and RSD 34%. Screening strategies are implemented in <10% targeted population, however pharmacotherapy/chemotherapy/surgery was comparable with international guidelines. The study reveals that prostate cancer incidences are highest among Sindhi Speaking and then Urdu Speakings. Rests of the ethnic groups are in the range of 7-10%. There is a need to implement the screening strategies more extensively to the small/basic/rural health care centers for early diagnosis of the disease and new treatments strategies especially in surgical management like application of cryosurgery, high intensity ultrasound and proton beam radiation therapy are making revolution in the management of prostate cancer.